FAP and interstitial lung disease: Preliminary studies in small cohorts of patients have shown increased FAP PET signal in a wide range of settings including cardiac injury, interstitial lung disease and pulmonary fibrosis, IgG4-related disease, cirrhosis, renal injury, inflammatory bowel disease and rheumatoid arthritis (18–21).